During my doctoral studies, I discovered that an ETP-like subtype of T-ALL is dependent on MYCN. Building upon preliminary results that indicate an important role of H3K4 methylation in controlling MYCN gene expression in these leukemias, my present research seeks to identify the key epigenetic modifiers responsible for establishing and/or maintaining H3K4 methylation in the context of T-ALL development. Ultimately, this investigation may unveil novel pharmacological targets for combating T-ALL.
Gabriela Segat, PhD
Postdoctoral Fellow

BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.